ImmunityBio data highlights highly individualized patient priorities in bladder cancer care
ImmunityBio (NASDAQ:IBRX) announced new survey data highlighting the highly individualized treatment preferences and quality-of-life priorities of patients navigating high-risk non-muscle-invasive bladder cancer (NMIBC).
The findings, presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2026 annual meeting in Philadelphia, examine how patients who have failed standard Bacillus Calmette–Guérin (BCG) therapy evaluate the choice between radical cystectomy—the complete surgical removal of the bladder—and emerging bladder-sparing alternatives.
The mixed-methods study was conducted in partnership with Fight Bladder Cancer, a UK-based patient advocacy group.
Researchers gathered quantitative insights from an online questionnaire of 86 UK adults with NMIBC who were either undergoing or had completed BCG regimens, supplementing the data with qualitative one-on-one interviews and focus group discussions.
The study revealed a sharp divergence in patient preferences based on age, sex, and prior clinical experiences.
Patients actively receiving BCG therapy strongly favored bladder preservation strategies, whereas those who had already undergone a radical cystectomy overwhelmingly supported repeating that surgical path in retrospect.
Conversely, older participants demonstrated a significantly lower preference for radical cystectomy.
While clinical efficacy parameters—such as overall life expectancy, tumor recurrence, and disease progression—remained the primary drivers of medical decisions across all demographics, quality-of-life considerations varied widely.
Notably, male participants expressed more acute concerns regarding the long-term lifestyle disruptions associated with radical organ removal.
The study authors concluded that there is no uniform solution for patients facing BCG failure.
Many individuals indicated a willingness to accept logistical trade-offs, including more frequent hospital visits for monitoring and maintenance, specifically to avoid undergoing a radical cystectomy.
